A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy

NCT03690388 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

187

Enrollment

INDUSTRY

Sponsor class

Conditions

Differentiated Thyroid Cancer

Interventions

DRUG: Cabozantinib
DRUG: Placebo

Sponsor

Exelixis

Collaborators

[object Object]